Patents by Inventor Vidya Ganapati Kattige

Vidya Ganapati Kattige has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of respiratory disorders using TRPA1 antagonists
    Patent number: 9186360
    Abstract: The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder using a TRPA1 antagonist, wherein the TRPA1 antagonist is administered by inhalation route to a subject in need thereof.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: November 17, 2015
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Neelima Khairatkar-Joshi, Abhay Kulkarni, Indranil Mukhopadhyay, Vidya Ganapati Kattige, Vikram Mansingh Bhosale, Dinesh Pradeep Wale, Abraham Thomas, Sukeerthi Kumar, Sachin Sundarlal Chaudhari
  • Triazolone compounds as mPGES-1 inhibitors
    Patent number: 9096545
    Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: August 4, 2015
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Laxmikant Atmaram Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • Bicyclic compounds as mPGES-1 inhibitors
    Patent number: 9006257
    Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: April 14, 2015
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Laxmikant Atmaram Gharat, Abhisek Banerjee, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • TRIAZOLONE COMPOUNDS AS mPGES-1 INHIBITORS
    Publication number: 20150087646
    Abstract: The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
    Type: Application
    Filed: June 10, 2013
    Publication date: March 26, 2015
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Laxmikant Atmaram Gharat, Nagarajan Muthukaman, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • Chromane derivatives as TRPV3 modulators
    Patent number: 8492568
    Abstract: The present invention provides chromane derivatives as transient receptor potential vanilloid (TRPV) modulators. In particular, the compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: July 23, 2013
    Assignee: Glenmark Pharamceuticals S.A.
    Inventors: V. S. Prasada Rao Lingam, Abraham Thomas, Javed Yusuf Khatik, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • Chromane derivatives as TRPV3 modulators
    Patent number: 8487121
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: July 16, 2013
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: V S Prasadarao Lingam, Abraham Thomas, Laxmikant Atmaram Gharat, Deepak Vitthal Ukirde, Shantaram Kashinath Phatangare, Ajit Shankar Mindhe, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • Fused pyrimidine derivatives as TRPV3 modulators
    Patent number: 8349846
    Abstract: The present invention related to fused pyrimidine derivatives, which are useful as Transient Receptor Potential Vanilloid 3 (TRPV3) receptors, methods of treating diseases, disorders, conditions modulated by TRPV3. The present invention having the formula (I) and its pharmaceutically acceptable salts thereof, and its processes thereof, wherein all variables are as described herein.
    Type: Grant
    Filed: January 7, 2009
    Date of Patent: January 8, 2013
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: V S. Prasadarao Lingam, Abraham Thomas, Dattaguru Anandrao More, Javed Yusuf Khatik, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • Fused imidazole derivatives as TRPV3 antagonist
    Patent number: 8344010
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: January 1, 2013
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: V. S. Prasadarao Lingam, Abraham Thomas, Shantaram Kashinath Phatangare, Ajit Shankar Mindhe, Javed Yusuf Khatik, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • TREATMENT OF RESPIRATORY DISORDERS USING TRPA1 ANTAGONISTS
    Publication number: 20120316136
    Abstract: The present patent application relates to treatment of a respiratory disorder using TRPA1 antagonists. Particularly, the present patent application relates to treatment of a respiratory disorder using a TRPA1 antagonist, wherein the TRPA1 antagonist is administered by inhalation route to a subject in need thereof.
    Type: Application
    Filed: June 13, 2012
    Publication date: December 13, 2012
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Neelima KHAIRATKAR-JOSHI, Abhay KULKARNI, Indranil MUKHOPADHYAY, Vidya Ganapati KATTIGE, Vikram Mansingh BHOSALE, Dinesh Pradeep WALE, Abraham THOMAS, Sukeerthi KUMAR, Sachin Sundarlal CHAUDHARI
  • Fused imidazole carboxamides as TRPV3 modulators
    Patent number: 8318928
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Grant
    Filed: December 11, 2009
    Date of Patent: November 27, 2012
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Sachin Sundarlal Chaudhari, Thomas Abraham, Ashok Bhausaheb Kadam, Sachin Vasantrao Dhone, Suresh Mahadev Kadam, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS
    Publication number: 20120108813
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Application
    Filed: January 11, 2012
    Publication date: May 3, 2012
    Inventors: Prasada Rao V.S. LINGAM, Sachin Sundarlal CHAUDHARI, Abraham THOMAS, Neelima KHAIRATKAR-JOSHI, Vidya Ganapati KATTIGE
  • Fused pyrimidineone compounds as TRPV3 modulators
    Patent number: 8119647
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: February 21, 2012
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Prasada Rao V. S. Lingam, Sachin Sundarlal Chaudhari, Abraham Thomas, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • FUSED IMIDAZOLE DERIVATIVES AS TRPV3 ANTAGONIST
    Publication number: 20110257193
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Application
    Filed: December 23, 2009
    Publication date: October 20, 2011
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: V. S. Prasadarao Lingam, Abraham Thomas, Shantaram Kashinath Phatangare, Ajit Shankar Mindhe, Javed Yusuf Khatik, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • CHROMENONE DERIVATIVES AS TRPV3 ANTAGONISTS
    Publication number: 20110237659
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Application
    Filed: November 6, 2009
    Publication date: September 29, 2011
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Sachin Sundarlal Chaudhari, Abraham Thomas, Ashok Bhausaheb Kadam, Sachin Vasantrao Dhone, Bharat Gangadhar Adik, Neelima Khairatkar-joshi, Vidya Ganapati Kattige
  • CHROMANE DERIVATIVES AS TRPV3 MODULATORS
    Publication number: 20110098316
    Abstract: The present invention provides chromane derivatives as transient receptor potential vanilloid (TRPV) modulators. In particular, the compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Application
    Filed: May 19, 2009
    Publication date: April 28, 2011
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: V.P. Prasada Rao Lingam, Abraham Thomas, Javed Yusuf Khatik, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • CHROMANE DERIVATIVES AS TRPV3 MODULATORS
    Publication number: 20100311778
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Application
    Filed: December 16, 2008
    Publication date: December 9, 2010
    Inventors: V S Prasadarao Lingam, Abraham Thomas, Laxmikant Atmaram Gharat, Deepak Vitthal Ukirde, Shantaram Kashinath Phatangare, Ajit Shankar Mindhe, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • Fused Pyrimidine Derivatives as Trpv3 Modulators
    Publication number: 20100292254
    Abstract: The present invention related to fused pyrimidine derivatives, which are useful as Transient Receptor Potential Vanilloid 3 (TRPV3) receptors, methods of treating deseases, disorders, conditions modulated by TRPV3. The present invention having the formula (I) and its pharmaceutically acceptable salts thereof, and its processes thereof, wherein all variables are as described herein.
    Type: Application
    Filed: January 7, 2009
    Publication date: November 18, 2010
    Applicant: GLENMARK PHARMACEUTICALS, S.A.
    Inventors: V S, Prasadarao Lingam, Abraham Thomas, Dattaguru Anandrao More, Javed Yusuf Khatik, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS
    Publication number: 20100152192
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators of formula (I). In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Application
    Filed: December 11, 2009
    Publication date: June 17, 2010
    Applicant: Glenmark Pharmaceuticals S.A
    Inventors: Sachin Sundarlal Chaudhari, Abraham Thomas, Ashok Bhausaheb Kadam, Sachin Vasantrao Dhone, Suresh Mahdadev Kadam, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige
  • FUSED PYRIMIDINEONE COMPOUNDS AS TRPV3 MODULATORS
    Publication number: 20090286811
    Abstract: The present invention provides transient receptor potential vanilloid (TRPV) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPV3. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPV3.
    Type: Application
    Filed: April 9, 2009
    Publication date: November 19, 2009
    Inventors: Prasada Rao V.S. Lingham, Sachin Sundarlal Chaudhari, Abraham Thomas, Neelima Khairatkar-Joshi, Vidya Ganapati Kattige